胃食管腺癌HER2检测与临床决策指南
美国病理学家协会、美国临床病理学会和美国临床肿瘤学会召集专家小组,系统综述文献,制定胃食管腺癌(GEA)HER2检测的循证指南。指南提出11条推荐,强调对所有适合HER2靶向治疗的晚期GEA患者应在治疗前评估HER2状态,HER2阳性者初始治疗应联合化疗与HER2靶向药物,并为病理医生提供形态学选择、检测算法、评分、判读和报告及实验室质量保证的指导。
要点
- 所有适合HER2靶向治疗的晚期GEA患者,初始治疗前应检测HER2状态。
- HER2阳性晚期GEA患者初始治疗推荐化疗联合HER2靶向药物。
- 指南为病理医生提供组织选择、检测算法、评分和报告等指导。
核心结论
- 该指南为晚期胃食管腺癌患者的HER2检测和临床决策提供了具体推荐。
研究设计与样本
- 美国病理学家协会、美国临床病理学会和美国临床肿瘤学会召集专家小组,系统综述文献制定循证指南。
主要发现
- 专家小组提出11条推荐,并获得公开评论参与者的强烈同意。
关键数值与推荐
- 推荐对所有适合HER2靶向治疗的晚期GEA患者,在开始HER2靶向治疗前评估HER2状态。
- 推荐HER2阳性晚期GEA患者初始治疗采用化疗联合HER2靶向药物。
- 为病理医生提供形态学选择肿瘤组织、检测算法、评分方法、判读和报告结果及实验室质量保证的指导。
临床怎么用
- 病理医生应按照指南进行HER2检测和报告,临床医生据此选择HER2靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: - ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. OBJECTIVES: - To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. DESIGN: - The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. RESULTS: - The panel is proposing 11 recommendations with strong agreement from the open-comment participants. RECOMMENDATIONS: - The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. CONCLUSIONS: - This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.
引用
- Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016. PMID: 27841667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。